Skin response using NIH consensus criteria vs Hopkins scale in a phase II study for steroid-refractory chronic GVHD

D. A. Jacobsohn, A. Rademaker, M. Kaup, G. B. Vogelsang

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

One of the obstacles to chronic GVHD research is the lack of standardized response criteria. The National Institute of Health (NIH) has recommended response criteria at a Consensus Conference. These need to be validated. We recently completed and reported a trial of pentostatin in treating steroid-refractory chronic GVHD. During the trial, we prospectively collected percent body-surface-area (BSA) involvement of rash, superficial sclerosis and deep sclerosis. Here, we compare cutaneous responses using the NIH scale and the Hopkins scale. The two scales produced similar overall response rates but different domain response rates. There was 80 agreement in overall response at the final treatment evaluation, but only a 64 agreement for fasciitisnon- moveable sclerosis. There was more disparity in the measurement of sclerosis than in that of erythema, which highlights the difficulty of quantifying sclerosis. For sclerosis, the Hopkins scale, which used skin softening, was more predictive of early response as compared with the NIH scale, which focused on percent BSA. Early assessment of skin softening may be important if trying to detect the activity of a particular agent in chronic GVHD. Further validation of the NIH scale is ongoing, which should produce a clinically useful and predictive scale.

Original languageEnglish (US)
Pages (from-to)813-819
Number of pages7
JournalBone Marrow Transplantation
Volume44
Issue number12
DOIs
StatePublished - Dec 13 2009

Keywords

  • Chronic GVHD
  • Graft-versus-host disease
  • NIH consensus criteria
  • Scale

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Skin response using NIH consensus criteria vs Hopkins scale in a phase II study for steroid-refractory chronic GVHD'. Together they form a unique fingerprint.

Cite this